Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2024 NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331–57.

Article  CAS  PubMed  Google Scholar 

Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32(20):2151–8.

Article  PubMed  Google Scholar 

Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142–50.

Article  PubMed  PubMed Central  Google Scholar 

Fasano GA, Bayard S, Chen Y, et al. Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2022;192(1):163–73.

Article  CAS  PubMed  Google Scholar 

Ho AY, Gupta G, King TA, et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 2012;118(20):4944–52.

Article  PubMed  Google Scholar 

Bosch AM, Kessels AG, Beets GL, et al. Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol. 2003;48(3):285–92.

Article  PubMed  Google Scholar 

Hieken TJ, Harrison J, Herreros J, Velasco JM. Correlating sonography, mammography, and pathology in the assessment of breast cancer size. Am J Surg. 2001;182(4):351–4.

Article  CAS  PubMed  Google Scholar 

Madjar H, Ladner HA, Sauerbrei W, Oberstein A, Prömpeler H, Pfleiderer A. Preoperative staging of breast cancer by palpation, mammography and high-resolution ultrasound. Ultrasound Obstet Gynecol. 1993;3(3):185–90.

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105–22.

Article  CAS  PubMed  Google Scholar 

Cortadellas T, Argacha P, Acosta J, et al. Estimation of tumor size in breast cancer comparing clinical examination, mammography, ultrasound and MRI-correlation with the pathological analysis of the surgical specimen. Gland Surg. 2017;6(4):330–5.

Article  PubMed  PubMed Central  Google Scholar 

Davis PL, Staiger MJ, Harris KB, et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat. 1996;37(1):1–9.

Article  CAS  PubMed  Google Scholar 

Gruber IV, Rueckert M, Kagan KO, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer. BMC Cancer. 2013;13:328.

Article  PubMed  PubMed Central  Google Scholar 

Sanli DET, Icten GE, Kul S, et al. Correlation of Radiological and Pathological Tumor Sizes in Breast Cancer Based on Molecular Subtypes and Accompanying DCIS: A Retrospective Multicenter Study. Acad Radiol. 2025;32(6):3511–8.

Article  PubMed  Google Scholar 

Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE. MRI versus ultrasonography and mammography for preoperative assessment of breast cancer. Am Surg. 2009;75(10):970–5.

Article  PubMed  Google Scholar 

Evans A, Pinder S, Wilson R, et al. Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol. 1994;162(6):1307–11.

Article  CAS  PubMed  Google Scholar 

Stomper PC, Geradts J, Edge SB, Levine EG. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. AJR Am J Roentgenol. 2003;181(6):1679–84.

Article  PubMed  Google Scholar 

Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009;16(10):2705–10.

Article  PubMed  Google Scholar 

Ha SM, Cha JH, Shin HJ, Chae EY, Choi WJ, Kim HH. Mammography, US, and MRI to assess outcomes of invasive breast cancer with extensive intraductal component: a matched cohort study. Radiology. 2019;292(2):299–308.

Article  PubMed  Google Scholar 

Botty van den Bruele A, Ferraro E, Sevilimedu V, et al. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? Breast Cancer Res Treat. 2021;189(2):307–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85.

Article  PubMed  Google Scholar 

Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27–35.

Article  CAS  PubMed  Google Scholar 

Dang C, Ewer MS, Delaloge S, et al. BERENICE final analysis: cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer. Cancers. 2022;14(11):2596.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978–84.

Article  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

Article  Google Scholar 

Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.

Article  CAS  PubMed  Google Scholar